

AperTO - Archivio Istituzionale Open Access dell'Università di Torino

**Diagnostic imaging to detect and evaluate response to therapy in bone metastases from prostate cancer: current modalities and new horizons**

**This is the author's manuscript**

*Original Citation:*

Diagnostic imaging to detect and evaluate response to therapy in bone metastases from prostate cancer: current modalities and new horizons / Evangelista, Laura; Bertoldo, Francesco; Boccardo, Francesco; Conti, Giario; Menchi, Ilario; Mungai, Francesco; Ricardi, Umberto; Bombardieri, Emilio. - In: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. - ISSN 1619-7070. - 43:8(2016), pp. 1546-1562.

*Availability:*

This version is available <http://hdl.handle.net/2318/1645741> since 2017-07-27T10:41:08Z

*Published version:*

DOI:10.1007/s00259-016-3350-4

*Terms of use:*

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)

This is the author's final version of the contribution published as:

Evangelista, Laura; Bertoldo, Francesco; Boccardo, Francesco; Conti, Giario; Menchi, Ilario; Mungai, Francesco; Ricardi, Umberto; Bombardieri, Emilio.  
Diagnostic imaging to detect and evaluate response to therapy in bone metastases from prostate cancer: current modalities and new horizons.  
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 43 (8) pp: 1546-1562.  
DOI: 10.1007/s00259-016-3350-4

The publisher's version is available at:

<http://link.springer.com/content/pdf/10.1007/s00259-016-3350-4>

When citing, please refer to the published version.

Link to this full text:

<http://hdl.handle.net/2318/1645741>

# Diagnostic imaging to detect and evaluate response to therapy in bone metastases from prostate cancer: current modalities and new horizons

Laura Evangelista<sup>1</sup> & Francesco Bertoldo<sup>2</sup> & Francesco Boccardo<sup>3</sup> & Giario Conti<sup>4</sup> & Ilario Menchi<sup>5</sup> & Francesco Mungai<sup>5</sup> & Umberto Ricardi<sup>6</sup> & Emilio Bombardieri<sup>7</sup>

**Abstract** Different therapeutic options for the management of prostate cancer (PC) have been developed, and some are successful in providing crucial improvement in both survival and quality of life, especially in patients with metastatic castration-resistant PC. In this scenario, diverse combinations of radiopharmaceuticals (for targeting bone, cancer cells and receptors) and nuclear medicine modalities (e.g. bone scan, SPECT, SPECT/CT, PET and PET/CT) are now available for imaging bone metastases. Some radiopharmaceuticals are approved, currently available and used in the routine clinical setting, while others are not registered and are still under evaluation, and should therefore be considered experimental. On the other hand, radiologists have other tools, in addition to CT, that can better visualize bone localization and medullary involvement, such as multimodal MRI. In this review, the authors provide an overview of current management of advanced PC and discuss the choice of diagnostic modality for the detection of metastatic skeletal lesions in different phases of the disease. In addition to detection of bone metastases, the evaluation of response to therapy is another critical issue, since it remains one of the most important open questions that a multidisciplinary team faces when optimizing the management of PC. The authors emphasize the role of nuclear modalities that can presently be used in clinical practice, and also look at future perspectives based on relevant clinical data with novel radiopharmaceuticals.

<sup>1</sup> Radiotherapy and Nuclear Medicine Unit, Veneto Institute of Oncology IOV – IRCCS, Padova, Italy <sup>2</sup> Department of Internal Medicine, School of Medicine, University of Verona, Verona, Italy <sup>3</sup> Academic Unit of Medical Oncology, IRCCSAOU San Martino-IST (San Martino University Hospital and National Cancer Research Institute), Genoa, Italy <sup>4</sup> Department of Urology, Sant' Anna Hospital, Como, Italy <sup>5</sup> Department of Diagnostic Imaging, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy <sup>6</sup> Department of Oncology, Radiation Oncology, University of Torino, Torino, Italy <sup>7</sup> Nuclear Medicine Department, Humanitas Gavazzeni, Via Gavazzeni 31, 24125 Bergamo, Italy

## Introduction

In recent years, prostate cancer (PC) has been an active field of research in terms of biology, diagnostic imaging and drug development. In particular, the widespread application of new diagnostic technologies is offering various strategies to detect bone metastases (BMT) and assess treatment response in patients with advanced disease. Therefore, the approach to the management of PC, particularly in patients with high-risk PC (i.e. at least one of the following characteristics: PSA >20 ng/mL, Gleason score (GS) ≥8, clinical stage T2c–3a in accordance with D'Amico classification) and with skeletal metastases, has rapidly changed. The relevance of skeletal metastases in patients affected by PC is well known, and their impact on survival, life expectancy and quality of life has been reported by many authors [1–6]. Until a few years ago, patients with skeletal metastases were treated only palliatively. Conversely, today the introduction of new drugs has provided both a delay in skeleton-related events (SREs) and a significant improvement in overall survival (OS) [7–18].

Knowledge of the number and the pattern of BMT is essential to choose the correct therapy and allow proper evaluation of tumour response. Several radiopharmaceutical agents are currently available and used in different diagnostic modalities, including bone scan (BS), SPECT, SPECT/CT, PET and PET/CT. The main challenges at present are to determine the best option to detect BMT in different phases of the disease and to measure changes in radiopharmaceutical uptake as an early sign of response to treatment or progression. National and international clinical guidelines still recommend traditional BS with <sup>99m</sup>Tc-phosphonates as the standard method for studying BMT, and only a few, in certain situations, suggest other nuclear medicine approaches, such as <sup>18</sup>F-fluoride and <sup>11</sup>C/<sup>18</sup>F-choline PET/CT, which have been validated in several clinical studies, and are registered and available for clinical use [19–21]. Thus, the time has come to stimulate open discussion about the role of different modalities based on bone-targeting agents

(<sup>99m</sup>Tc-phosphonate BS, <sup>99m</sup>Tc-phosphonate SPECT/CT and <sup>18</sup>F-fluoride PET/CT) and cancer-targeting agents (<sup>11</sup>C/<sup>18</sup>F-choline PET/CT, <sup>18</sup>F-FDG PET/CT) compared with the diagnostic options offered by radiology (e.g. CT and MRI). In addition, rapid progress in radiopharmacy research has led to the development of new receptor-targeting radiopharmaceutical agents such as <sup>68</sup>Ga/<sup>18</sup>F-PSMA, which has been the subject of intense clinical assessment in several European countries with very promising results. Therefore, this field is a fertile area of discussion and debate. We review the current status regarding the management of BMT in PC patients by summarizing the most relevant achievements from pathogenesis to treatment. New scientific knowledge on the physiopathology of BMT formation, markers of bone remodelling, main diagnostic strategies and novel treatments for advanced disease are presented. Most discussion is focused on analysis of the advantages and disadvantages offered by currently available diagnostic tools in nuclear medicine and radiology, and their current position in the diagnostic work-up of patients with skeletal metastatic disease. <sup>68</sup>Ga/<sup>18</sup>F-PSMA, <sup>18</sup>F-FACBC and <sup>18</sup>F-bombesin are still considered as experimental radiopharmaceutical agents, and therefore are not fully available in clinical practice or are already registered by regulatory authorities. However, in the present manuscript, we will give more attention to <sup>68</sup>Ga-PSMA that represents the most interesting tracers up to now. Pathogenesis of bone metastases BMT are observed in approximately 3 – 6 % of patients with newly diagnosed PC, and 11.5 % of patients who are metastasis-free at baseline develop BMT after about 2 years of follow-up [10, 22]. In advanced stage PC, skeletal involvement is present in about 90 % of patients with metastatic disease [23, 24]. From autopsy data, 35 % of patients with advanced PC will develop haematogenous metastases and, in 90 % of such patients, the metastases will be localized in the bone [25, 26]. However, there is a wide range in reported incidence (between 35 % and 70 %) that varies depending on the study characteristics, population and follow-up period [27–29]. Given the increasing sensitivity of imaging modalities such as PET/CT and improvement in survival using new therapies, the number of PC patients with metastases at diagnosis is likely to increase and the visceral/skeletal ratio is likely to change [30]. BMT is a multistep process and its complex pathogenesis is not yet fully clarified. High bone turnover induced by androgen ablation is a predisposing condition to the homing and dissemination of tumour cells to bone marrow [31]. In animal models, there is evidence that PC cells home to sites of osteoblast-rich niches at an early stage [32]. The osteoblastic lesion is the result of releasing osteoblast-promoting factors from PC cells, and it has recently been demonstrated that osteocytes are also critical mediators in the bone metastatic niches. Therefore, targeting bone turnover at an early stage may be a useful strategy for preventing BMT in PC patients. BMT in PC are usually defined as **B**one **M**etastatic **T** by conventional plain radiography. However, recent studies have shown a high heterogeneity of lesions with synchronous osteolysis and blastic lesions [33]. Histomorphometric studies have shown that blastic lesions are mixed in nature with increased activities of both osteoblasts and osteoclasts [34]. The under-mineralized woven bone and the osteopenic/osteolytic component of BMT may contribute to the skeletal frailty observed in PC patients with metastases, even in those with dense metastatic lesions [35]. BMT most commonly affect the axial skeleton and pelvis, and patients with confined disease in the vertebrae have a better prognosis. Several authors have attempted to correlate the extent of skeletal metastatic involvement, number of metastases and distribution with survival of patients affected by advanced PC [8, 14, 16]. For example, patients with metastatic castration-resistant PC (mCRPC) with a higher number of BMT (more than five) showed shorter progression-free survival and OS than those with fewer than five lesions (HR 2.0, 95 % CI 1.7 – 2.4) [17]. Moreover, BMT can worsen the quality of life and survival through an increased risk of complications. The term SRE is a composite endpoint for research purposes used to group complications such as fractures and/or spinal cord compression that require radiotherapy and pre-emptive bone surgery. Pathological fractures are common, and the commonest sites for fractures are the vertebral bodies and long bones. The most serious complications are impingement of the spinal cord, impeded anabolism due to mandatory castration therapy, and deterioration of general status that are the leading causes of hospitalization and death.

In patients with mCRPC, the rate of SRE has been reported to be 44.2 % after 15 months in the placebo arm of a randomized clinical trial of zoledronic acid [7]. Oster et al. found that more than half (51.7 %) of PC patients experience an SRE during follow-up [13]. Interestingly, there are no differences in terms of incidence of SRE and median survival time after SRE between osteoblastic and osteolytic BMT. However, pathological fractures and hypercalcaemia are slightly more frequent in osteolytic than osteoblastic BMT (52 % vs. 25 %, respectively). Conversely, spinal cord compression is more frequent in osteoblastic than for lytic BMT (8 % vs. 3 %, respectively). Radiation or surgery to bone are used at similar rates for both types of bone lesions [36]. Between 1998 and 2010, the rate of SRE in PC patients decreased from 18% to 15.4 %, and SRE-associated mortality decreased from 8.5 % to 4.7 % [37]. The SEER-Medicare dataset (1999 – 2009) shows that the HR of PC-specific mortality associated with SRE ranges from 1.07 to 1.31, and is also associated with spinal cord compression and pathological fractures [10–12, 15]. More recently, other researchers have investigated whether novel molecular approaches might provide additional prognostic information in patients with BMT. Indeed, it has been shown that BMT in mCRPC patients express higher levels of androgen receptor (AR) splice variants, such as AR-V7 and AR567e, than BMT in hormone-naïve patients. The overexpression of AR variants is usually correlated with poorer prognosis and resistance to endocrine therapies [38].

## **Current treatments**

Nowadays, physicians can choose among several effective alternative treatments for mCRPC. Adequate management of patients with BMT should guarantee a correct balance of efficacy, symptom control and prevention of disease complications. Both chemotherapy with docetaxel and cabazitaxel [39–44], and novel endocrine therapies such as abiraterone acetate and enzalutamide [45–47] have been shown to have a favourable impact on survival in mCRPC. More recently, docetaxel has been shown to improve life expectancy of hormone-naïve patients with high risk and high tumour burden when combined with androgen deprivation treatments [42]. Up to now, although several beta emitters are available for palliative treatment of BMT, only the alpha emitter <sup>223</sup>Ra chloride has demonstrated a survival advantage in symptomatic mCRPC patients, with limited myelotoxicity [48]; this drug is now recommended in both chemo-naïve patients and patients who have received docetaxel when symptomatic bone disease is present [48, 49].

The appropriate algorithm for use of available drugs is still an area of open discussion. If palliation is the main purpose, bone-modifying agents including bisphosphonates and the inhibitor of the RANK/RANKL pathway, denosumab, can be used to reduce the risk of SRE and improve the bone pain control in symptomatic patients [50], although denosumab has been shown to be superior to zoledronic acid in delaying and preventing SREs. None of these agents, however, is associated with improvement in OS. External beam radiotherapy is also an effective palliative treatment for control of pain due to BMT. It can achieve significant clinical results in 60 – 80 % of patients, with up to half of patients obtaining complete pain relief at the treated site [51, 52]. Numerous prospective randomized trials, meta-analyses and systematic reviews have shown similar pain relief outcomes with single-fraction schedules (8 Gy) compared with longer courses of palliative radiotherapy in BMT from a variety of primary malignancies [52–54]. The available evidence supports the use of single-fraction radiotherapy as a standard for all uncomplicated BMT from PC, because of its positive effects on several types of endpoints (e.g. response rates, response duration, re-treatment rates, toxicity, cost-effectiveness [55–57]).

## **Methods to study bone metastases**

### **Clinical evaluation and PSA**

Pain is a common symptom in PC patients with skeletal metastases, with a prevalence of about 75 % [58]. Recognizing the cause of pain is a prerequisite for a correct and rational therapeutic approach to improve and/or preserve quality of life, avoid or delay SREs and, whenever possible, to prolong survival [59]. Patient examination and administration of appropriate questionnaires is needed using validated and standardized tools, such as the visual analogue scale and World Health Organization score [60]; a multidisciplinary approach to evaluate patients and establish the optimal approach should be implemented at the early stages of disease. At present, prostate-specific antigen (PSA) is commonly used for detecting tumour presence, extension and growth. PSA is also considered for monitoring chemotherapy treatments, although for drugs targeting BMT it is reliable since it is a marker for tumour, and not bone remodelling. It is generally accepted that a 50 % decrease in PSA levels compared with initial values is predictive of good metabolic response, and is often associated with better survival [61]. However, even in this setting, changes in PSA can show unexpected trends [62]. Recent recommendations from the Prostate Cancer Clinical Trials Working Group (PCWG2 and PCWG3) of the American Society of Clinical Oncology define PSA progression, during or after therapy, as the date that a 25 % or greater increase and an absolute increase of 2 ng/mL or more from when nadir is documented and confirmed by a second value obtained  $\geq 3$  weeks later [30, 63].

### **Markers of bone turnover**

Continuous skeletal remodelling by osteoclast bone resorption and osteoblast bone formation can be quantified using serum and urinary biochemical parameters, or so-called markers of bone turnover. BMT are characterized by high focal bone turnover with increased levels of osteolysis and/or osteogenesis. For this reason, biochemical markers of bone remodeling might be an ideal tool to monitor progression of osteolytic or osteoblastic metastasis and/or response to treatment. At present, serum procollagen type I N-propeptide, s-PINP, and serum C-terminal telopeptide of type I collagen, s-CTX, are recommended as gold standard markers of bone formation and bone resorption, respectively [12]. The clinical utility of bone markers as diagnostic indicators of bone metastatic disease and as prognostic indicators has been extensively examined. Several studies have revealed an association between bone turnover marker and presence or progression of skeletal metastases from PC [64–67]. Bone alkaline phosphatase (ALP) had the highest diagnostic accuracy (72 % sensitivity, 88 % specificity) and PINP the highest diagnostic specificity (92 %) [67]. Retrospective analyses of data from the phase III trials of zoledronic acid in patients with mCRPC and BMT showed that both baseline and on-study elevation in bone marker levels, in particular NTX and bone ALP, were associated with increased risks of SRE, disease progression and death [68–70]. A high baseline level of urinary NTX ( $>180$  nmol/mmol creatinine) was associated with a more than 2.5-fold increase in the risk of death (RR 2.58, 95 % CI 1.92 – 3.47) compared with a low baseline level of NTX ( $<55$  nmol/mmol creatinine), and an increase in baseline bone ALP was associated with a 4 % increase in the risk of death and SRE per 200 UI/L increase [68–70]. Recently, bone ALP velocity ( $>6.3$  UI/L/year) has been found to be an independent predictor of OS in patients with mCRPC. A fivefold increase in the risk of death was observed among mCRPC patients with rapid bone ALP velocity (HR 5.11  $< 95$  % CI 2.24 – 11.67) [71]. Moreover, CTX or NTX in association with PINP have prognostic significance as bone markers [72]. However, in cancer patients serum or urinary levels of bone turnover markers may be high for several concomitant causes such as age, vitamin D deficiency and adjuvant hormone therapy in addition to BMT, and it is impossible to distinguish the contribution of the different components that elevate the levels of bone markers [73].

In summary, the current clinical utilization of bone turnover markers for diagnosis, prognosis and monitoring therapy in PC patients with skeletal metastases remains of high interest, but cannot be recommended at present. There is, however, an objective need for harmonization, standardization

and common reference ranges for reproducible significance of bone biomarkers in routine practice [74–76].

## **Radiological imaging**

Conventional plain radiography, often in association with <sup>99m</sup>Tc-diphosphonate BS, CT and MRI, can be used in the assessment of prostatic bone disease, with varying results, as confirmed by data in the literature (Table 1). Plain radiography was historically the first imaging modality available for assessing bone and BMT. Plain radiography is readily available and usually easy for the patient. Although not particularly sensitive (30 – 75 % of trabecular bone must be destroyed before osseous destruction is detectable on a conventional plain radiograph), plain radiography does give an overview of the status of a particular bone segment, and in the absence of Bred flag^ symptoms, it is a good preliminary investigation. In addition, it is simple and cost effective, especially in symptomatic patients, and allows the assessment of potential complications such as pathological fractures. However, neither systematic bone screening nor evaluation of treatment response of BMT by conventional plain radiography are currently used in clinical practice because of their low diagnostic accuracy; indeed, radiographic signs of therapeutic response of bone lesions (peripheral sclerosis, lesion filling, and condensation) are delayed by several months, ambiguous, or absent despite clinical improvement [86, 87]. Peripheral sclerosis is observed only in osteolytic lesions, which are observed in only 10 % of patients with bone metastatic PC. Conversely, condensation is more frequent in mixed or osteoblastic lesions. CT is well suited to bone imaging. The availability of CT has increased greatly in recent years and the speed and quality of image reconstruction has been substantially enhanced. CT allows finely detailed assessment of osseous architecture, including the cortex and trabecular framework, and detects much smaller areas of trabecular destruction/invasion than visible by plain radiography alone. CT is also particularly helpful in assessing areas that can be difficult to visualize by plain radiography, such as the sacrum. For evident radioprotection reasons, CT targets a particular portion of the body and is not used for whole-body (WB) bone screening in clinical applications, although in some situations it is routinely employed. Moreover, CT scans are limited in their ability to assess therapeutic response because bone structure rarely normalizes even with completely effective therapy. The appearance of new or worsening bone sclerosis on CT in patients is occasionally and erroneously classified as disease progression (CT flare response) by inexperienced radiologists. RECIST criteria (v. 1.1) allow individual osteolytic or mixed osteolytic/osteoblastic metastases to be measured if there is a soft-tissue component, but diffuse disease and osteoblastic BMT are considered non-evaluable [88, 89]. Furthermore, other observations (e.g. lack of change, appearance of new sclerotic areas) should be considered more cautiously and should not be taken into account in evaluation of response. Plain radiography and CT detect neoplastic bone lesions at a late stage, i.e. weeks or months after the appearance of tumour cells within the bone marrow, because they rely on the activation of bone cells – osteoblasts and osteoclasts – to detect lesions. MRI is sensitive to early changes in bone marrow that precede the osteoclastic/osteoblastic response of the bone matrix to tumour infiltration before bone trabeculae or cortices are affected by disease. The superiority of MRI for detection of BMT over both plain radiography and CT (often as Baddons^ to bone scintigraphy) has been widely demonstrated (Table 1). The availability of the technique, its repeatability, lack of irradiation and its ability to provide WB evaluation have contributed to the development of MRI as the tool of choice for detection and follow-up of BMT. As an adjunct to conventional T1-weighted and STIR (short tau inversion recovery) acquisitions, diffusion-weighted imaging (DWI) sequences are also currently employed. DWI is able to detect changes in water diffusion that occur when normal fatty marrow is replaced with highly dense cellularity that restricts normal water movements among cell membranes. The advent of WB protocols with excellent image resolution and shortening of acquisition times, and the developmentWB DWIand Ball-organ^ capabilities, justify the increasing use of WB MRI at many centres [79, 90]. DWI provides morphological (qualitative)

and functional (quantitative) information on BMT. Qualitatively, reconstructed maximum intensity projection (MIP) or multi-parametric projection (MPR) images of DWI, covering the whole body or only the central skeleton, provide an easy <sup>Bat a glance</sup> qualitative evaluation of tumour burden, and focus attention on areas that are difficult to analyse on anatomic images. Several pitfalls in the visual analysis of DWI images must be recognized. As DWI not only reflects the cellular load but also the water content of tissues, benign conditions such as degenerative joint diseases, fractures, postirradiation changes and benign tumours (angiomas) may show high signal intensity on DWI images. The technique may also present false-negative findings, mainly in sclerotic or calcified metastases. These shortcomings underline the need for a systematic correlation of DWI images with conventional sequences. In this regard, T1-weighted images are the most helpful, in particular when acquired using the 3D protocol, which has been demonstrated to increase the sensitivity in detection of lesions [91].

The technique also shows great promise for assessment of response. DWI is able to detect changes in water diffusion that occur after therapy as a result of changes in cellular density and loss of membrane integrity. The impeded water mobility observed in tumour tissue will decrease or disappear in relation to the loss of cellular integrity in response to treatment, for example owing to cellular necrosis. Comparison of consecutive examinations provides a rapid and generally nonambiguous qualitative evaluation of disease response or progression during therapy. DWI also allows the measurement of the apparent diffusion coefficient (ADC, units  $\times 10^{-3}$  mm<sup>2</sup>/s), which provides functional (quantitative) assessment of tumour lesions. Generally, a tumour focus shows decreased ADC values in relation to increased cellularity and restricted mobility of protons in water. DWI is able to detect an increase in ADC in PC metastases treated with antiandrogen therapy as early as 1 month after treatment initiation [92, 93]. The effectiveness of ADC monitoring to predict the response of BMT to therapy is, however, controversial. The interpretation of changes in ADC values is indeed complex, mainly because of heterogeneity of both the tumour and response to treatment. Newer analysis methods (ADC parametric response or functional diffusion map) taking into account spatial information and tumour heterogeneity enable careful voxel-by-voxel follow-up of treatment-induced changes and evaluation of the proportion of tumour tissues in which significant changes occur [94]. These approaches seem to be able to detect very early changes (such as an increase in ADC) after treatment initiation. However, ADC can be used routinely only after optimization of hardware, sequences, signal analysis and definitive standardization of the acquisition method to improve the reliability of the results. Evaluation of reproducibility of ADC measurements is also a priority [94].

In conclusion, MRI (especially with the use of WB and DWI acquisitions) has a well-established role for the detection of metastases, but evaluation of response to therapy is challenging due to the heterogeneity of disease and the mainly osteoblastic nature of metastases. Areas of sclerosis are often present at the time of diagnosis and may increase following treatment, even with other signs of response to treatment. When this occurs, neither DWI nor anatomic imaging appears to be useful in giving the correct response. In fact, the sclerotic lesion may actually appear larger and/or the evaluation of its diffusion coefficient may be controversial. MRI appears to be a more reliable tool for: confirming stable disease when the size of measurable bone lesions remains unchanged and no new lesions are found; corroborating progressive disease when new lesions are seen or if a sclerotic lesion shows a new peripheral halo (hypointense on T1-weighted imaging and hyperintense on DWI as signs of increased cellularity and restricted diffusion) [79]. Therefore, the potential of MRI in evaluation of treatment response is still being studied, and only a limited amount of data are currently available [95].

### **Nuclear medicine imaging**

Nuclear medicine offers several options for the detection of BMT in PC patients: (a) BS as planar or tomographic imaging (i.e. single photon emission tomography, SPET) and (b) PET/ CT with 18F-



fluoride or 18F-FDG, 11C/18F-choline or 11C-acetate, 68Ga-PSMA, or 18F-FACBC. Each imaging technique has a specific mechanism of action in the detection of BMT due to differences in uptake and metabolism among the radiopharmaceuticals. Therefore, each technique is associated with different diagnostic performance that is mainly based on the type of skeletal lesion (i.e. osteoblastic vs. osteolytic vs. bone marrow invasion) [96–98]. At present, 11C-acetate, 68Ga-PSMA and 18F-FACBC are still considered experimental radiopharmaceutical agents. These agents are not employed in routine clinical practice, and 11C-acetate, 68Ga-PSMA and 18F-FACBC are not discussed further in this review; however, the increasing data on 68Ga-PSMA in PC patients studied in several European countries has shown a promising role for this tracer in BMT detection, and this agent is discussed in the section New horizons in the detection of bone metastases and evaluation of response to treatment. Planar BS using 99mTc-diphosphonates is the standard technique for the detection of skeletal metastasis from PC as it is widely available, relatively inexpensive and highly sensitive. However, the mechanism of uptake of 99mTc to a suitable phosphonate that allows imaging of sites of blastic or mixed lesions, and not areas where a calcium deposit is lacking, limits the use of this radiopharmaceutical. For this reason, BS shows low specificity (falsely positive in benign lesions, prior trauma and arthritis) and flare phenomena. Therefore, an osteoblastic response that occurs as a result of bone healing/ flare response during systemic treatment can significantly alter its diagnostic performance and make clinical interpretation of scintigraphic findings very difficult. Moreover, in a large retrospective analysis, BMT were found in less than 1 % of patients with PSA <20 ng/mL, with a negative predictive value of 99.7 % [99]. Leucovet et al. found that in 100 patients with high-risk PC the sensitivity of BS increased from 80% to 86 % when it was added to targeted plain radiography [79]. However, although the introduction of tomographic imaging such as SPET and SPET/CT has overcome some of the limitations of BS, these modalities are not able to cover the entire body of the patient. An interesting possibility offered by BS is calculation of the BS index, which better reflects the extent of metastatic disease [100]. This approach is noteworthy since its measurement can be automated, although the technique has not shown value in routine clinical practice [101]. Even with persistently high costs, PET is an efficient modality for WB scanning in a reasonably short time. With the increasing availability of PET/CT scanners and standardized acquisition protocols on different PET scanners, the possibility of obtaining more detailed and precise CT anatomic localizations of PET-directed metabolic abnormalities of tumour lesions, especially in skeletal diseases, has become a clinical reality. Moreover, PET is able to provide quantitative and semiquantitative information by

May, 2012 October, 2012 February, 2013 Fig. 2 A 68-year-old man with prostate cancer treated by radical prostatectomy (pT3aN0Mx, Gleason score 10; positive margins and extracapsular invasion) and adjuvant radiotherapy in 2010. May 2012 In 2012, for biochemical recurrence of disease (PSA 15.55 ng/mL), he was staged by 18F-choline PET/CT that showed metastatic bone recurrence of disease. He was started on bicalutamide and LHRH analogues. October 2012 Due to a further increase in PSA (141 ng/mL after 4 months), 18F-choline PET/CT was repeated that showed progression of metabolic disease. Therefore, the attending oncologist suggested switching the treatment from androgen deprivation therapy to chemotherapy (docetaxel + prednisone). February 2013 After 4 months, PSA had reduced to 33.6 ng/mL and 18F-choline PET/CT showed a good response to chemotherapy Eur J Nucl Med Mol Imaging (2016) 43:1546–1562 1555 using reproducible standardized quantification methods [102] that are useful for comparing serial examinations, especially before, during and after therapy. Nowadays, many radiopharmaceutical agents are available for PET/CT imaging, especially for the detection of BMT. 18F-Fluoride, a hydroxyapatite stabilizer, has the desirable characteristics of high and rapid bone uptake accompanied by very rapid blood clearance, which results in a high bone-to-background ratio in a short time. 18F/11C-Choline is a substrate of phospholipid metabolism which is usually enhanced in PC that is able to identify the presence of viable cancer tissue; promising results, especially for early detection of bone marrow infiltration, have been obtained. 18F-FDG is mainly used for definition of osteolytic lesions [57], but seems to be able to identify the presence of viable cells in

osteoblastic ones, even if the majority of PC displays low glycolytic metabolic behaviour, which would suggest that its current use may not be optimal. Generally, high uptake of 18F-FDG is expected in prostate tumours that are poorly differentiated, hypoxic and have a high GS. However, it can be used to assess the extent of metabolically active castrate-resistant prostate disease.

Table 2 summarizes the performance of each imaging modality. As shown, the median sensitivity of 18F-fluoride PET/ CT is the highest in comparison to the other modalities for the detection of BMT in PC patients. However, it should be underlined that in many studies bone disease is often measured on follow-up imaging, such as CT, BS, or MRI, while histological assessment is not performed, mainly for ethical reasons. Conversely, both 11C-choline and 18F-choline PET/ CT show higher specificity than BS or 18F-fluoride PET/CT. This result can be linked to the different behaviour of 18F/11C-choline in osteoarticular disease. Moreover, as expected, 18F-FDG PET/CT has low sensitivity (between 56 % and 72 %) in the detection of BMT in patients with PC, although as suggested by several authors, and as mentioned above, it may occasionally be suitable for prostate imaging in a limited subset of selected patients with aggressive histology and poorly differentiated cancer [111, 117–119].

Considering the areas of assessment of response to therapy, all of the above-mentioned metabolic methods may have value since their uptake is linked to the phenomenon of bone remodelling or to the metabolic activity of neoplastic cells. Most of the available data relate to BS as for decades this has been the most widely used modality to study skeletal lesions and still remains the most common. There are limited data regarding other modalities, even if there is a progressive increase in their use. The most recent data available in the literature demonstrate a role for radiolabelled choline PET/ CT in assessment of new hormonal therapies, such as enzalutamide [120, 121] or abiraterone acetate [122], and chemotherapy (i.e. docetaxel) [123]. The findings of radiolabelled choline PET/CT have been compared to PSA changes in order to determine the response to therapy. Choline PET/CT findings agree with PSA changes in the majority of patients with progressive disease, during and after therapy; on the contrary, PET/CT is able to identify only a moderate number of patients with partial or complete response to therapy. However, the disappearance of uptake does not always correlate with the disappearance of the cancer lesion since it could be due to the effect of a stable or nonmetabolically active focus. In contrast, the appearance of new areas of uptake does not always correlate with certain progression due to the well-known phenomenon of flare reaction, whose correct interpretation in BS has been standardized. This issue is an open area of debate.

### **New horizons in the detection of bone metastases and evaluation of response to treatment**

The majority of national and international guidelines for PC, such as EAU [20], AUA [124], ESMO [49] and NCCN [21], mainly recommend using PSA levels, BS and abdominopelvic CT to determine the presence of cancer and monitor treatment response. Moreover, in some recent clinical trials [41, 43, 46, 48, 90, 125], PSA, CT and BS have been used to evaluate tumour response to therapy in mCRPC patients. However, MRI has a greater ability to detect more skeletal lesions and earlier than CT; in addition, it is currently used as a **Bproblemsolving**<sup>^</sup> technique when a lesion is reported as **Bindeterminate**<sup>^</sup>. However, MRI cannot be proposed as an alternative method for diagnosis of skeletal metastasis or for monitoring response to treatment because of its limited field of view (which can be overcome with WB MRI that is now available in a few centres) and restricted interpretation criteria when bone sclerosis is present at the metastatic site (such as RECIST).

Although CT remains the most widespread imaging technique for detection of cancer, it is important to underline that RECIST criteria can be used for assessment of visceral metastases, but cannot be employed for evaluation of response to therapy in BMT, considering their anatomic features and biological behaviour. Therefore, the integration of PSA, other appropriate bone biomarkers such as ALP and morphological imaging with metabolic techniques can provide

additional information that is reliable for monitoring changes occurring inside the tumour and bone structure. As already mentioned, BS continues to be used in clinical practice since it has advantages in terms of cost, availability and execution, even if it has low diagnostic specificity and cannot detect medullary and osteolytic lesions. The hybrid modality SPET/CT can improve the accuracy of planar BS, but has a limited field of view like MRI and still suffers from the limitation of the poor specificity. <sup>18</sup>F-Fluoride PET/CT can improve the sensitivity in detecting BMT, and also has other advantages, including better quality of images and shorter acquisition time. <sup>18</sup>F/<sup>11</sup>C Choline and <sup>18</sup>F-FDG PET/CT are able to visualize both skeletal and nonskeletal metastases. In some studies, both metabolic radiopharmaceutical agents have been used to assess response to therapy [120–123, 126, 127], but data are still preliminary. Table 3 summarizes the strengths and weaknesses of the currently employed radiological and nuclear medicine modalities in clinical practice for evaluation of bone lesions in patients with PC. The development of new receptor tracers, such as <sup>68</sup>Ga-PSMA, has opened new approaches to the management of PC, although they are still experimental. The most significant advantages of <sup>68</sup>Ga-PSMA PET/CT are the sensitive detection of lesions, even at low PSA levels (i.e. PSA <1 ng/mL), small lymph node metastases (primarily due to high radiotracer uptake) and central bone and liver metastases due to low background signal. However, PSMA imaging should be approached with caution because of the limited information in the form of published data. From current data, the detection rate of BMT with <sup>68</sup>Ga-PSMA is 37 % [96, 130–133] compared to 32.1 % with choline PET/CT [115, 134–138] (Tables 4 and 5). However, continuing research will probably soon provide more information on the use of <sup>68</sup>Ga-PSMA (Figs. 1 and 2). Eur J Nucl Med Mol Imaging (2016) 43:1546–1562 1557 To date, on the basis of approved diagnostic instruments and radiopharmaceutical agents, we can summarize the evidence discussed above in a flow-chart to localize disease (BMT, monitor evolution and whenever possible obtain prognostic information). According to the site of recurrence, patients with PC can be classified as having bone-dominant (only skeletal involvement) or no bone-dominant disease (no skeletal, lymph node, visceral, or soft-tissue invasion; Fig. 3). Based on the extent of dissemination of disease, the most appropriate diagnostic tool to visualize BMT can be chosen based on disease grade (i.e. low grade, GS ≤7, or high grade, GS 8 – 10). Therefore, to detect lesions in bone-dominant disease, all patients with PC who are candidates for bone-targeted therapies, such as <sup>223</sup>Ra, could benefit from those techniques targeting bone modalities (BS and SPET or <sup>18</sup>F-fluoride PET/CT). BS is still considered the standard method of choice, but could be replaced by <sup>18</sup>F-fluoride PET/CT given its higher sensitivity. Moreover, since PET is always performed with CT (as PET/CT), the use of CT as a stand-alone examination for analysis of bone can be avoided. Additionally, MRI can be used to better characterize the structure of metastatic lesions and as a Bproblem-solving^ technique when an indeterminate lesion is found. In patients with bone-dominant disease and a GS ≥8 – 10, <sup>18</sup>F-FDG PET/CT as a bone-targeting modality would be of value to obtain predictive information on both response to therapy and prognosis. Thus in patients with poorly differentiated disease, <sup>18</sup>F-FDG PET/CT could be adopted. However, considering the limited utility of <sup>18</sup>F-FDG PET/CT and the metabolic heterogeneity of PC, it should be considered together with other cancer or receptor-specific radiopharmaceutical agents such as radiolabelled choline and/or PSMA. Each imaging scan should be repeated, as suggested by the PCWG2, at the end of antitumour therapy unless more frequent assessments are required by the treatment protocol (2 – 3 months) or by the development of signs or symptoms suggesting tumour progression, or if a flare reaction is suspected. In these cases, it should be repeated after 3 months. On the other hand, in patients with non-bone-dominant disease <sup>18</sup>F/<sup>11</sup>C-choline PET/CT and CT should preferably be used for follow-up, since radiolabelled choline scan can visualize both visceral and skeletal lesions, while CT is adequate to follow visceral lesions, especially those in the liver. If more accurate skeletal evaluation is required, MRI or <sup>18</sup>F-fluoride PET/CT can be substituted for CT. In this subset of patients, radiolabelled choline PET/CT should be used during therapy (every 3 – 6 months according to PCWG2 and the recent recommendations of the St. Gallen Consensus Conference [63, 139]) and at the end of therapy, or on the basis of changes in PSA level. <sup>18</sup>F-

Choline PET/CT should be repeated within 3 months if a flare phenomenon is suspected (as described during abiraterone treatment). Lastly, there are two main advantages of including nuclear medicine imaging in monitoring the response to therapy in PC patients: to evaluate the effects of different targeting therapies on the metabolism of PC cells and to assess the state of the disease in relation to the timing of treatments.

**Acknowledgments** The authors are grateful to the following specialists who participated in the discussion of this proposal. Gianluigi Ciocia, MD, Nuclear Medicine Department, Humanitas Gavazzeni, Bergamo, Italy; Marialuisa De Rimini, MD, U.O.C. of Nuclear Medicine, A.O.R.N. Monaldi, Naples, Italy; Stefano Fanti, MD, Nuclear Medicine Department, Azienda Ospedaliera Universitaria di Bologna, Bologna, Italy; Chiara Maria Grana, MD, Nuclear Medicine Division, Istituto Europeo di Oncologia, Milan, Italy; Lorenzo Maffioli, MD, Nuclear Medicine Department, Ospedale Civile di Legnano, Legnano (Milan), Italy; Marcello Rodari, MD, Nuclear Medicine Department, Humanitas Clinical and Research Institute, Rozzano (Milan), Italy; Rosa Sciuto, MD, Department of Nuclear Medicine, Regina Elena National Cancer Institute, Roma, Italy; Francesco Scopinaro, MD, Unit of Nuclear Medicine, Sant'Andrea Hospital, Rome, Italy, and Department of Surgical and Medical Sciences and Translational Medicine, Sapienza University of Rome, Rome, Italy. All authors attended an editorial meeting hosted by Health Publishing & Services srl to discuss topics for inclusion. The entire project was made possible thanks to unconditional support from Bayer. Editorial assistance for the manuscript was provided by Dr. Patrick Moore, on behalf of Health Publishing & Services srl and supported by Bayer.

## References

1. Gater A, Abetz-Webb L, Battersby C, Parasuraman B, McIntosh S, Nathan F, et al. Pain in castration-resistant prostate cancer with bone metastases: a qualitative study. *Health Qual Life Outcomes*. 2011;9:88. doi:10.1186/1477-7525-9-88.
2. Kirby M, Hirst C, Crawford ED. Characterising the castration-resistant prostate cancer population: a systematic review. *Int J Clin Pract*. 2011;65:1180–92. doi:10.1111/j.1742-1241.2011.02799.x.
3. Lee RJ, Saylor PJ, Smith MR. Contemporary therapeutic approaches targeting bone complications in prostate cancer. *Clin Genitourin Cancer*. 2010;8:29–36. doi:10.3816/CGC.2010.n.005.
4. Lipton A, Cook R, Brown J, Body JJ, Smith M, Coleman R. Skeletal-related events and clinical outcomes in patients with bone metastases and normal levels of osteolysis: exploratory analyses. *Clin Oncol (R Coll Radiol)*. 2013;25:217–26. doi:10.1016/j.clon.2012.11.004.
5. Saad F, Clarke N, Colombel M. Natural history and treatment of bone complications in prostate cancer. *Eur Urol*. 2006;49:429–40. doi:10.1016/j.eururo.2005.12.045.
6. Smith MR, Kabbinavar F, Saad F, Hussain A, Gittelman MC, Bilhartz DL, et al. Natural history of rising serum prostatespecific antigen in men with castrate nonmetastatic prostate cancer. *J Clin Oncol*. 2005;23:2918–25. doi:10.1200/JCO.2005.01.529.
7. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. *Clin Cancer Res*. 2006;12:6243s–9s. doi:10.1158/1078-0432.CCR-06-0931.
8. Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. *N Engl J Med*. 1989;321:419–24. doi:10.1056/NEJM198908173210702.
9. Doctor SM, Tsao CK, Godbold JH, Galsky MD, Oh WK. Is prostate cancer changing?: evolving patterns of metastatic castration-resistant prostate cancer. *Cancer*. 2014;120:833–9. doi:10.1002/cncr.28494.
10. Norgaard M, Jensen AO, Jacobsen JB, Cetin K, Fryzek JP, Sorensen HT. Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007). *J Urol*. 2010;184:162–7. doi:10.1016/j.juro.2010.03.034.

11. Oefelein MG, Ricchiuti V, Conrad W, Resnick MI. Skeletal fractures negatively correlate with overall survival in men with prostate cancer. *J Urol*. 2002;168:1005–7. doi:10.1097/01.ju.0000024395.86788.cc.
12. Onukwugha E, Yong C, Mullins CD, Seal B, McNally D, Hussain A. Skeletal-related events and mortality among older men with advanced prostate cancer. *J Geriatr Oncol*. 2014;5:281–9. doi:10.1016/j.jgo.2014.03.002.
13. Oster G, Lamerato L, Glass AG, Richert-Boe KE, Lopez A, Chung K, et al. Natural history of skeletal-related events in patients with breast, lung, or prostate cancer and metastases to bone: a 15-year study in two large US health systems. *Support Care Cancer*. 2013;21:3279–86. doi:10.1007/s00520-013-1887-3.
14. Sabbatini P, Larson SM, Kremer A, Zhang ZF, Sun M, Yeung H, et al. Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. *J Clin Oncol*. 1999;17:948–57.
15. Sathiakumar N, Delzell E, Morrisey MA, Falkson C, Yong M, Chia V, et al. Mortality following bone metastasis and skeletal-related events among women with breast cancer: a population-based analysis of U.S. Medicare beneficiaries, 1999–2006. *Breast Cancer Res Treat*. 2012;131:231–8. doi:10.1007/s10549-011-1721-x.
16. Soloway MS, Hardeman SW, Hickey D, Raymond J, Todd B, Soloway S, et al. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. *Cancer*. 1988;61:195–202.
17. Tait C, Moore D, Hodgson C, Brown M, Morris T, Growcott J, et al. Quantification of skeletal metastases in castrate-resistant prostate cancer predicts progression-free and overall survival. *BJU Int*. 2014;114:E70–3. doi:10.1111/bju.12717.
18. Vargas HA, Wassberg C, Fox JJ, Wibmer A, Goldman DA, Kuk D, et al. Bone metastases in castration-resistant prostate cancer: associations between morphologic CT patterns, glycolytic activity, and androgen receptor expression on PET and overall survival. *Radiology*. 2014;271:2209. doi:10.1148/radiol.13130625.
19. Beheshti M, Mottaghy FM, Payche F, Behrendt FF, Van den Wyngaert T, Fogelman I, et al. (18)F-NaF PET/CT: EANM procedure guidelines for bone imaging. *Eur J Nucl Med Mol Imaging*. 2015;42:1767–77. doi:10.1007/s00259-015-3138-y.
20. Heidenreich A, Aus G, Bolla M, Joniau S, Matveev VB, Schmid HP, et al. EAU guidelines on prostate cancer. *Eur Urol*. 2008;53: 68–80. doi:10.1016/j.eururo.2007.09.002.
21. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Prostate cancer. 2015. Available at: [http://www.nccn.org/professionals/physician\\_gls/f\\_guidelines.asp](http://www.nccn.org/professionals/physician_gls/f_guidelines.asp). Accessed 21 Oct 2015.
22. Miller DC, Hafez KS, Stewart A, Montie JE, Wei JT. Prostate carcinoma presentation, diagnosis, and staging: an update from the National Cancer Data Base. *Cancer*. 2003;98:1169–78. doi: 10.1002/cncr.11635.
23. Jacobs SC. Spread of prostatic cancer to bone. *Urology*. 1983;21: 337–44.
24. Scher HI, Morris MJ, Kelly WK, Schwartz LH, Heller G. Prostate cancer clinical trial end points: BRECISTing a step backwards. *Clin Cancer Res*. 2005;11:5223–32. doi:10.1158/10780432.CCR-05-0109.
25. Bubendorf L, Schopfer A, Wagner U, Sauter G, Moch H, Willi N, et al. Metastatic patterns of prostate cancer: an autopsy study of 1589 patients. *Hum Pathol*. 2000;31:578–83.
26. Freedland SJ, Richhariya A, Wang H, Chung K, Shore ND. Treatment patterns in patients with prostate cancer and bone metastasis among US community-based urology group practices. *Urology*. 2012;80:293–8. doi:10.1016/j.urology.2012.04.007.
27. Tofe AJ, Francis MD, Harvey WJ. Correlation of neoplasms with incidence and localization of skeletal metastases: an analysis of 1355 diphosphonate bone scans. *J Nucl Med*. 1975;16:986–9.

28. Wang CY, Wu GY, Shen MJ, Cui KW, Shen Y. Comparison of distribution characteristics of metastatic bone lesions between breast and prostate carcinomas. *Oncol Lett.* 2013;5:391–7. doi:10.3892/ol.2012.1005.
29. Wilson MA, Calhoun FW. The distribution of skeletal metastases in breast and pulmonary cancer: concise communication. *J Nucl Med.* 1981;22:594–7.
30. Sher HI. The Prostate Cancer Working Group 3 (PCWG3) consensus for trials in castration-resistant prostate cancer (CRPC). ASCO Annual Meeting 2015. Chicago; 2015.
31. Ottewell PD, Wang N, Meek J, Fowles CA, Croucher PI, Eaton CL, et al. Castration-induced bone loss triggers growth of disseminated prostate cancer cells in bone. *Endocr Relat Cancer.* 2014;21:769–81. doi:10.1530/ERC-14-0199.
32. Wang N, Docherty FE, Brown HK, Reeves KJ, Fowles AC, Ottewell PD, et al. Prostate cancer cells preferentially home to osteoblast-rich areas in the early stages of bone metastasis: evidence from in vivo models. *J Bone Miner Res.* 2014;29:2688–96. doi:10.1002/jbmr.2300.
33. Goltzman D. Mechanisms of the development of osteoblastic metastases. *Cancer.* 1997;80:1581–7.
34. Clarke NW, McClure J, George NJ. Morphometric evidence for bone resorption and replacement in prostate cancer. *Br J Urol.* 1991;68:74–80.
35. Roudier MP, Morrissey C, True LD, Higano CS, Vessella RL, Ott SM. Histopathological assessment of prostate cancer bone osteoblastic metastases. *J Urol.* 2008;180:1154–60. doi:10.1016/j.juro.2008.04.140.
36. Fang J, Xu Q. Differences of osteoblastic bone metastases and osteolytic bone metastases in clinical features and molecular characteristics. *Clin Transl Oncol.* 2015;17:173–9. doi:10.1007/s12094-014-1247-x.
37. Jayasekera J, Onukwugha E, Bikov K, Mullins CD, Seal B, Hussain A. The economic burden of skeletal-related events among elderly men with metastatic prostate cancer. *Pharmacoeconomics.* 2014;32:173–91. doi:10.1007/s40273-013-0121-y.
38. Boccardo F. The MAINSAIL trial: an expected failure. *Lancet Oncol.* 2015;16:355–6. doi:10.1016/S1470-2045(15)70058-6.
39. Horwich A, Parker C, de Reijke T, Kataja V, Group EGW. Prostate cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. *Ann Oncol.* 2013;24 Suppl 6:vi106–14. doi:10.1093/annonc/mdt208.
40. James MD, Sydes MR, Mason MD. Docetaxel (DOC) +/- zoledronic acid for hormone-naive prostate cancer: first available results from STAMPEDE and treatment effects within subgroups (NCT00268476). *Eur J Cancer.* 2015;51:abstract 19LBC:S719.
41. Petrylak DP, Tangen CM, Hussain MH, Lara Jr PN, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. *N Engl J Med.* 2004;351:1513–20. doi:10.1056/NEJMoa041318.
42. Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. *N Engl J Med.* 2015;373: 737–46. doi:10.1056/NEJMoa1503747.
43. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. *N Engl J Med.* 2004;351:1502–12. doi:10.1056/NEJMoa040720.
44. van Soest RJ, Nieuweboer AJ, de Morree ES, Chitu D, Bergman AM, Goey SH, et al. The influence of prior novel androgen receptor targeted therapy on the efficacy of cabazitaxel in men with metastatic castration-resistant prostate cancer. *Eur J Cancer.* 2015;51:2562–9. doi:10.1016/j.ejca.2015.07.037.
45. Attard G, Reid AH, A'Hern R, Parker C, Oommen NB, Folkard E, et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. *J Clin Oncol.* 2009;27:3742–8. doi:10.1200/JCO.2008.20.0642.

46. Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. *N Engl J Med*. 2014;371:424–33. doi:10.1056/NEJMoa1405095.
47. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. *N Engl J Med*. 2011;364:1995–2005. doi:10.1056/NEJMoa1014618.
48. Sartor O, Coleman R, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, et al. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bonemetastases: results from a phase 3, double-blind, randomized trial. *Lancet Oncol*. 2014;15:738–46. doi:10.1016/S1470-2045(14)70183-4.
49. Parker C, Gillessen S, Heidenreich A, Horwich A, Committee EG. Cancer of the prostate: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2015;26 Suppl 5: v69–77. doi:10.1093/annonc/mdv222.
50. Saad F, McKiernan J, Eastham J. Rationale for zoledronic acid therapy in men with hormone-sensitive prostate cancer with or without bone metastasis. *Urol Oncol*. 2006;24:4–12. doi:10.1016/j.urolonc.2005.06.020.
51. Chow E, Harris K, Fan G, Tsao M, Sze WM. Palliative radiotherapy trials for bone metastases: a systematic review. *J Clin Oncol*. 2007;25:1423–36. doi:10.1200/JCO.2006.09.5281.
52. Lutz S, Berk L, Chang E, Chow E, Hahn C, Hoskin P, et al. Palliative radiotherapy for bone metastases: an ASTRO evidence-based guideline. *Int J Radiat Oncol Biol Phys*. 2011;79:965–76. doi:10.1016/j.ijrobp.2010.11.026.
53. Fairchild A, Barnes E, Ghosh S, Ben-Josef E, Roos D, Hartsell W, et al. International patterns of practice in palliative radiotherapy for painful bone metastases: evidence-based practice? *Int J Radiat Oncol Biol Phys*. 2009;75:1501–10. doi:10.1016/j.ijrobp.2008.12.084.
54. Hartsell WF, Scott CB, Bruner DW, Scarantino CW, Ivker RA, Roach 3rd M, et al. Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases. *J Natl Cancer Inst*. 2005;97:798–804. doi:10.1093/jnci/dji139.
55. Konski A. Radiotherapy is a cost-effective palliative treatment for patients with bone metastasis from prostate cancer. *Int J Radiat Oncol Biol Phys*. 2004;60:1373–8. doi:10.1016/j.ijrobp.2004.05.053.
56. Ricardi U, Filippi AR, Franco P. New concepts and insights into the role of radiation therapy in extracranial metastatic disease. *Expert Rev Anticancer Ther*. 2013;13:1145–55. doi:10.1586/14737140.2013.846829.
57. Yoon F, Morton GC. Single fraction radiotherapy versus multiple fraction radiotherapy for bone metastases in prostate cancer patients: comparative effectiveness. *Cancer Manag Res*. 2014;6: 451–7. doi:10.2147/CMAR.S44940.
58. van den Beuken-van Everdingen MH, de Rijke JM, Kessels AG, Schouten HC, van Kleef M, Patijn J. Prevalence of pain in patients with cancer: a systematic review of the past 40 years. *Ann Oncol*. 2007;18:1437–49. doi:10.1093/annonc/mdm056.
59. Portenoy RK, Koh M. Cancer pain syndromes. In: Bruera E, Portenoy RK, editors. *Cancer pain assessment and management*. Cambridge: Cambridge University Press; 2010.
60. van Herk R, van Dijk M, Baar FP, Tibboel D, de Wit R. Observation scales for pain assessment in older adults with cognitive impairments or communication difficulties. *Nurs Res*. 2007;56:34–43.
61. Smith DC, Dunn RL, Strawderman MS, Pienta KJ. Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer. *J Clin Oncol*. 1998;16:1835–43.
62. Thuret R, Massard C, Gross-Goupil M, Escudier B, Di Palma M, Bossi A, et al. The postchemotherapy PSA surge syndrome. *Ann Oncol*. 2008;19:1308–11. doi:10.1093/annonc/mdn062.

63. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. *J Clin Oncol*. 2008;26:1148–59. doi:10.1200/JCO.2007.12.4487.
64. Costa L, Demers LM, Gouveia-Oliveira A, Schaller J, Costa EB, de Moura MC, et al. Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status. *J Clin Oncol*. 2002;20:850–6.
65. Koizumi M, Yonese J, Fukui I, Ogata E. The serum level of the amino-terminal propeptide of type I procollagen is a sensitive marker for prostate cancer metastasis to bone. *BJU Int*. 2001;87:348–51.
66. Koopmans N, de Jong IJ, Breeuwsma AJ, van der Veer E. Serum bone turnover markers (PINP and ICTP) for the early detection of bone metastases in patients with prostate cancer: a longitudinal approach. *J Urol*. 2007;178:849–53. doi:10.1016/j.juro.2007.05.029.
67. Zafeirakis AG, Papatheodorou GA, Limouris GS. Clinical and imaging correlations of bone turnover markers in prostate cancer patients with bone only metastases. *NuclMed Commun*. 2010;31:249–53. doi:10.1097/MNM.0b013e328335a5ed.
68. Coleman RE, Major P, Lipton A, Brown JE, Lee KA, Smith M, et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. *J Clin Oncol*. 2005;23:4925–35. doi:10.1200/JCO.2005.06.091.
69. Cook RJ, Coleman R, Brown J, Lipton A, Major P, Hei YJ, et al. Markers of bone metabolism and survival in men with hormone refractory metastatic prostate cancer. *Clin Cancer Res*. 2006;12:3361–7. doi:10.1158/1078-0432.CCR-06-0269.
70. Smith MR, Cook RJ, Coleman R, Brown J, Lipton A, Major P, et al. Predictors of skeletal complications in men with hormone refractory metastatic prostate cancer. *Urology*. 2007;70:315–9. doi:10.1016/j.urology.2007.03.071.
71. Metwalli AR, Rosner IL, Cullen J, Chen Y, Brand T, Brassell SA, et al. Elevated alkaline phosphatase velocity strongly predicts overall survival and the risk of bone metastases in castrate resistant prostate cancer. *Urol Oncol*. 2014;32:761–8. doi:10.1016/j.urolonc.2014.03.024.
72. Brasso K, Christensen IJ, Johansen JS, Teisner B, Garnero P, Price PA, et al. Prognostic value of PINP, bone alkaline phosphatase, CTX-I, and YKL-40 in patients with metastatic prostate carcinoma. *Prostate*. 2006;66:503–13. doi:10.1002/pros.20311.
73. Michaelson MD, Marujo RM, Smith MR. Contribution of androgen deprivation therapy to elevated osteoclast activity in men with metastatic prostate cancer. *Clin Cancer Res*. 2004;10:2705–8.
74. Bauer D, Krege J, Lane N, Leary E, Libanati C, Miller P, et al. National Bone Health Alliance Bone Turnover Marker Project: current practices and the need for US harmonization, standardization, and common reference ranges. *Osteoporos Int*. 2012;23:2425–33. doi:10.1007/s00198-012-2049-z.
75. Coleman R, Costa L, Saad F, Cook R, Hadji P, Terpos E, et al. Consensus on the utility of bone markers in the malignant bone disease setting. *Crit Rev Oncol Hematol*. 2011;80:411–32. doi:10.1016/j.critrevonc.2011.02.005.
76. Vasikaran S, Eastell R, Bruyere O, Foldes AJ, Garnero P, Griesmacher A, et al. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. *Osteoporos Int*. 2011;22:391–420. doi:10.1007/s00198-010-1501-1.
77. Lecouvet FE, Geukens D, Stainier A, Jamar F, Jamart J, d’Othee BJ, et al. Magnetic resonance imaging of the axial skeleton for detecting bone metastases in patients with high-risk prostate cancer: diagnostic and cost-effectiveness and comparison with current detection strategies. *J Clin Oncol*. 2007;25:3281–7. doi:10.1200/JCO.2006.09.2940.



78. Ketelsen D, Rothke M, Aschoff P, Merseburger AS, Lichy MP, Reimold M, et al. Detection of bonemetastasis of prostate cancer – comparison of whole-body MRI and bone scintigraphy. *Rofo*. 2008;180:746–52. doi:10.1055/s-2008-1027479.
79. Lecouvet FE, El Mouedden J, Collette L, Coche E, Danse E, Jamar F, et al. Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc 99m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer? *Eur Urol*. 2012;62:68–75. doi:10.1016/j.eururo.2012.02.020.
80. Luboldt W, Kufer R, Blumstein N, Toussaint TL, Kluge A, Seemann MD, et al. Prostate carcinoma: diffusion-weighted imaging as potential alternative to conventionalMRand 11C-choline PET/CT for detection of bone metastases. *Radiology*. 2008;249: 1017 25.doi:10.1148/radiol.2492080038.
81. Venkitaraman R, Cook GJ, Dearnaley DP, Parker CC, Khoo V, Eeles R, et al. Whole-body magnetic resonance imaging in the detection of skeletal metastases in patients with prostate cancer. *J Med Imaging Radiat Oncol*. 2009;53:241–7. doi:10.1111/j.1754- 9485.2009.02070.x.
82. Wang X, Zhang C, Jiang X. Prospective study of bone metastasis from prostate cancer: comparison between large field diffusionweighted imaging and bone scintigraphy. *Chin J Radiol*. 2009;43: 131–5.
83. Gutzeit A, Doert A, Froehlich JM, Eckhardt BP, Meili A, Scherr P, et al. Comparison of diffusion-weighted whole body MRI and skeletal scintigraphy for the detection of bone metastases in patients with prostate or breast carcinoma. *Skelet Radiol*. 2010;39: 333–43. doi:10.1007/s00256-009-0789-4.
84. Mosavi F, Johansson S, Sandberg DT, Turesson I, Sorensen J, Ahlstrom H. Whole-body diffusion-weighted MRI compared with (18)F-NaF PET/CT for detection of bone metastases in patients with high-risk prostate carcinoma. *AJR Am J Roentgenol*. 2012;199:1114–20. doi:10.2214/AJR.11. 8351
85. Stecco A, Lombardi M, Leva L, Brambilla M, Negru E, Delli Passeri S, et al. Diagnostic accuracy and agreement between whole-body diffusion MRI and bone scintigraphy in detecting bone metastases. *Radiol Med*. 2013;118:465–75. doi:10.1007/ s11547-012-0870-2.
86. Galasko CS. Diagnosis of skeletal metastases and assessment of response to treatment. *Clin Orthop Relat Res*. 1995;312:64–75.
87. Hamaoka T, Madewell JE, Podoloff DA, Hortobagyi GN, Ueno NT. Bone imaging in metastatic breast cancer. *J Clin Oncol*. 2004;22:2942–53. doi:10.1200/JCO.2004.08.181.
88. Bauerle T, Semmler W. Imaging response to systemic therapy for bone metastases. *Eur Radiol*. 2009;19:2495–507. doi:10.1007/ s00330-009-1443-1.
89. Costelloe CM, Chuang HH, Madewell JE, Ueno NT. Cancer response criteria and bone metastases: RECIST 1.1, MDA and PERCIST. *J Cancer*. 2010;1:80–92.
90. Schmidt GP, Reiser MF, Baur-Melnyk A. Whole-body MRI for the staging and follow-up of patientswithmetastasis. *Eur J Radiol*. 2009;70:393–400. doi:10.1016/j.ejrad.2009.03.045.
91. Pasoglou V, Michoux N, Peeters F, Larbi A, Tombal B, Selleslagh T, et al. Whole-body 3D T1-weighted MR imaging in patients with prostate cancer: feasibility and evaluation in screening for metastatic disease. *Radiology*. 2015;275:155–66. doi:10.1148/ radiol.14141242.
92. Koh DM, Takahara T, Imai Y, Collins DJ. Practical aspects of assessing tumors using clinical diffusion-weighted imaging in the body. *Magn Reson Med Sci*. 2007;6:211–24.
93. Reischauer C, Froehlich JM, KohDM, Graf N, Padevit C, John H, et al. Bone metastases from prostate cancer: assessing treatment response by using diffusion-weighted imaging and functional diffusion maps – initial observations. *Radiology*. 2010;257:523–31. doi:10.1148/radiol.10092469.
94. Koh DM, Blackledge M, Collins DJ, Padhani AR, Wallace T, Wilton B, et al. Reproducibility and changes in the apparent diffusion coefficients of solid tumours treated with combretastatin A4 phosphate and bevacizumab in a two-centre phase I clinical trial. *Eur Radiol*. 2009;19:2728–38. doi:10.1007/s00330-009- 1469-4.

95. Fitzpatrick JM, Bellmunt J, Fizazi K, Heidenreich A, Sternberg CN, Tombal B, et al. Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel. *Eur J Cancer*. 2014;50:1617–27. doi: 10.1016/j.ejca.2014.03.010.
96. Afshar-Oromieh A, Zechmann CM, Malcher A, Eder M, Eisenhut M, Linhart HG, et al. Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. *Eur J Nucl Med Mol Imaging*. 2014;41:11–20. doi:10.1007/s00259-013-2525-5.
97. Even-Sapir E, Metser U, Mishani E, Lievshitz G, Lerman H, Leibovitch I. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. *J Nucl Med*. 2006;47:287–97.
98. Nanni C, Schiavina R, Brunocilla E, Borghesi M, Ambrosini V, Zanoni L, et al. 18F-FACBC compared with 11C-choline PET/CT in patients with biochemical relapse after radical prostatectomy: a prospective study in 28 patients. *Clin Genitourin Cancer*. 2014;12: 106–10. doi:10.1016/j.clgc.2013.08.002.
99. Briganti A, Passoni N, Ferrari M, Capitanio U, Suardi N, Gallina A, et al. When to perform bone scan in patients with newly diagnosed prostate cancer: external validation of the currently available guidelines and proposal of a novel risk stratification tool. *Eur Urol*. 2010;57:551–8. doi:10.1016/j.eururo.2009.12.023.
100. Dennis ER, Jia X, Mezheritskiy IS, Stephenson RD, Schoder H, Fox JJ, et al. Bone scan index: a quantitative treatment response biomarker for castration-resistant metastatic prostate cancer. *J Clin Oncol*. 2012;30:519–24. doi:10.1200/JCO.2011.36.5791.
101. Ulmert D, Kaboteh R, Fox JJ, Savage C, Evans MJ, Lilja H, et al. A novel automated platform for quantifying the extent of skeletal tumour involvement in prostate cancer patients using the bone scan index. *Eur Urol*. 2012;62:78–84. doi:10.1016/j.eururo.2012. 01.037.
102. Gamez-Cenzano C, Pino-Sorroche F. Standardization and quantification in FDG-PET/CT imaging for staging and restaging of malignant disease. *PET Clin*. 2014;9:117–27. doi:10.1016/j.cpet. 2013.10.003.
103. Garcia JR, Moreno C, Valls E, Cozar P, Bassa P, Soler M, et al. Diagnostic performance of bone scintigraphy and (11)C-choline PET/CT in the detection of bone metastases in patients with biochemical recurrence of prostate cancer. *Rev Esp Med Nucl Imagen Mol*. 2015;34:155–61. doi:10.1016/j.remnm.2014.08.001.
104. Poulsen MH, Petersen H, Hoiland-Carlson PF, Jakobsen JS, Gerke O, Karstoft J, et al. Spine metastases in prostate cancer: comparison of technetium-99m-MDP whole-body bone scintigraphy, [18F]choline positron emission tomography (PET)/computed tomography (CT) and [18F]NaF PET/CT. *BJU Int*. 2014;114:818– 23. doi:10.1111/bju.12599.
105. Iagaru A, Mitra E, Dick DW, Gambhir SS. Prospective evaluation of (99m)Tc MDP scintigraphy, (18)F NaF PET/CT, and (18)F FDG PET/CT for detection of skeletal metastases. *Mol Imaging Biol*. 2012;14:252–9. doi:10.1007/s11307-011-0486-2.
106. Damle NA, Bal C, Bandopadhyaya GP, Kumar L, Kumar P, Malhotra A, et al. The role of 18F-fluoride PET-CT in the detection of bone metastases in patients with breast, lung and prostate carcinoma: a comparison with FDG PET/CT and 99mTc-MDP bone scan. *Jpn J Radiol*. 2013;31:262–9. doi:10.1007/s11604- 013-0179-7.
107. Palmedo H, Marx C, Ebert A, Kreft B, Ko Y, Turler A, et al. Whole-body SPECT/CT for bone scintigraphy: diagnostic value and effect on patient management in oncological patients. *Eur J Nucl Med Mol Imaging*. 2014;41:59–67. doi:10.1007/s00259- 013-2532-6.
108. Withofs N, Grayet B, Tancredi T, Rorive A, Mella C, Giacomelli F, et al. (18)F-fluoride PET/CT for assessing bone involvement in prostate and breast cancers. *NuclMed Commun*. 2011;32:168–76. doi:10.1097/MNM.0b013e3283412ef5.

109. Takesh M, Odat Allh K, Adams S, Zechmann C. Diagnostic role of (18)F-FECH-PET/CT compared with bone scan in evaluating the prostate cancer patients referring with biochemical recurrence. *ISRN Oncol.* 2012;2012:815234. doi:10.5402/2012/815234.
110. Beheshti M, Vali R, Waldenberger P, Fitz F, Nader M, Hammer J, et al. The use of F-18 choline PET in the assessment of bone metastases in prostate cancer: correlation with morphological changes on CT. *Mol Imaging Biol.* 2009;11:446–54. doi:10.1007/s11307-009-0217-0.
111. Langsteger W, Heinisch M, Fogelman I. The role of fluorodeoxyglucose, 18F-dihydroxyphenylalanine, 18F-choline, and 18F-fluoride in bone imaging with emphasis on prostate and breast. *Semin Nucl Med.* 2006;36:73–92. doi:10.1053/j.semnuclmed.2005.09.002.
112. McCarthy M, Siew T, Campbell A, Lenzo N, Spry N, Vivian J, et al. (18)F Fluoromethylcholine (FCH) PET imaging in patients with castration-resistant prostate cancer: prospective comparison with standard imaging. *Eur J Nucl Med Mol Imaging.* 2011;38: 14–22. doi:10.1007/s00259-010-1579-x.
113. Beheshti M, Vali R, Waldenberger P, Fitz F, Nader M, Loidl W, et al. Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET-CT: a comparative study. *Eur J Nucl Med Mol Imaging.* 2008;35:1766–74. doi:10.1007/s00259-008-0788-z
114. Fuccio C, Castellucci P, Schiavina R, Santi I, Allegri V, Pettinato V, et al. Role of 11C-choline PET/CT in the restaging of prostate cancer patients showing a single lesion on bone scintigraphy. *Ann Nucl Med.* 2010;24:485–92. doi:10.1007/s12149-010-0390-x.
115. Picchio M, Spinapolice EG, Fallanca F, Crivellaro C, Giovacchini G, Gianolli L, et al. [11C]Choline PET/CT detection of bone metastases in patients with PSA progression after primary treatment for prostate cancer: comparison with bone scintigraphy. *Eur J Nucl Med Mol Imaging.* 2012;39:13–26. doi:10.1007/s00259-011-1920-z.
116. Kitajima K, Murphy RC, Nathan MA, Froemming AT, Hagen CE, Takahashi N, et al. Detection of recurrent prostate cancer after radical prostatectomy: comparison of 11C-choline PET/CT with pelvic multiparametric MR imaging with endorectal coil. *J Nucl Med.* 2014;55:223–32. doi:10.2967/jnumed.113.123018.
117. Hetzel M, Hetzel J, Arslanemir C, Nussle K, Schirrmeister H. Reliability of symptoms to determine use of bone scans to identify bone metastases in lung cancer: prospective study. *BMJ.* 2004;328:1051–2. doi:10.1136/bmj.328.7447.1051.
118. Schirrmeister H, Arslanemir C, Glatting G, Mayer-Steinacker R, Bommer M, Dreinhofer K, et al. Omission of bone scanning according to staging guidelines leads to futile therapy in non-small cell lung cancer. *Eur J Nucl Med Mol Imaging.* 2004;31:964–8. doi:10.1007/s00259-004-1492-2.
119. Steinborn MM, Heuck AF, Tiling R, Bruegel M, Gauger L, Reiser MF. Whole-body bone marrow MRI in patients with metastatic disease to the skeletal system. *J Comput Assist Tomogr.* 1999;23: 123–9.
120. Caffo O, Maines F, Donner D, Veccia A, Chierichetti F, Galligioni E. Impact of enzalutamide administration on primary prostate cancer volume: a metabolic evaluation by choline positron emission tomography in castration-resistant prostate cancer patients. *Clin Genitourin Cancer.* 2014;12:312–6. doi:10.1016/j.clgc.2014.03.004.
121. De Giorgi U, Caroli P, Scarpi E, Conteduca V, Burgio SL, Menna C, et al. (18)F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide. *Eur J Nucl Med Mol Imaging.* 2015;42: 1276–83. doi:10.1007/s00259-015-3042-5.
122. De Giorgi U, Caroli P, Burgio SL, Menna C, Conteduca V, Bianchi E, et al. Early outcome prediction on 18F-fluorocholine PET/CT in metastatic castration-resistant prostate cancer patients treated with abiraterone. *Oncotarget.* 2014;5:12448–58.
123. Ceci F, Castellucci P, Graziani T, Schiavina R, Renzi R, Borghesi M, et al. (11)C-Choline PET/CT in castration-resistant prostate cancer patients treated with docetaxel. *Eur J Nucl Med Mol*

Imaging. 2016;43:84–91. doi:10.1007/s00259-015-3177-4.

124. Cookson MS, Roth BJ, Dahm P, Engstrom C, Freedland SJ, Hussain M, et al. Castration-resistant prostate cancer: AUA guideline. American Urological Association; 2015.

125. Sternberg CN, Petrylak DP, Sartor O, Witjes JA, Demkow T, Ferrero JM, et al. Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. *J Clin Oncol*. 2009;27:5431–8. doi:10.1200/JCO.2008.20.1228.

126. Jadvar H. Prostate cancer: PET with 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline. *J Nucl Med*. 2011;52:81–9. doi:10.2967/jnumed.110.077941.

127. Wade AA, Scott JA, Kuter I, Fischman AJ. Flare response in 18F-fluoride ion PET bone scanning. *AJR Am J Roentgenol*. 2006;186:1783–6. doi:10.2214/AJR.05.0225.

128. McNamara MA, George DJ. Pain, PSA flare, and bone scan response in a patient with metastatic castration-resistant prostate cancer treated with radium-223, a case report. *BMC Cancer*. 2015;15:371. doi:10.1186/s12885-015-1390-y.

129. Jadvar H, Desai B, Ji L, Groshen S, Mills J, Murray R, et al. Prediction of hormonal resistance in metastatic prostate cancer with FDG PET/CT. *J Nucl Med*. 2015;56 Suppl 3:Abstract 1451.

130. Afshar-Oromieh A, Avtzi E, Giesel FL, Holland-Letz T, Linhart HG, Eder M, et al. The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. *Eur J Nucl Med Mol Imaging*. 2015;42: 197–209. doi:10.1007/s00259-014-2949-6.

131. Afshar-Oromieh A, Haberkorn U, Schlemmer HP, Fenchel M, Eder M, Eisenhut M, et al. Comparison of PET/CT and PET/ MRI hybrid systems using a 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience. *Eur J Nucl Med Mol Imaging*. 2014;41:887–97. doi:10.1007/s00259-013-2660-z.

132. Maurer T, Weirich G, Schottelius M, Weineisen M, Frisch B, Okur A, et al. Prostate-specific membrane antigen-radioguided surgery for metastatic lymph nodes in prostate cancer. *Eur Urol*. 2015;68: 530–4. doi:10.1016/j.eururo.2015.04.034.

133. Morigi JJ, Stricker PD, van Leeuwen PJ, Tang R, Ho B, Nguyen Q, et al. Prospective comparison of 18F-fluoromethylcholine versus 68Ga-PSMA PET/CT in prostate cancer patients who have rising PSA after curative treatment and are being considered for targeted therapy. *J Nucl Med*. 2015;56:1185–90. doi:10.2967/jnumed.115.160382.

134. Castellucci P, Fuccio C, Rubello D, Schiavina R, Santi I, Nanni C, et al. Is there a role for (11)C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml? *Eur J Nucl Med Mol Imaging*. 2011;38:55–63. doi:10.1007/s00259-010-1604-0.

135. Ceci F, Castellucci P, Graziani T, Schiavina R, Chondrogiannis S, Bonfiglioli R, et al. 11C-choline PET/CT identifies osteoblastic and osteolytic lesions in patients with metastatic prostate cancer. *Clin Nucl Med*. 2015;40:e265–70. doi:10.1097/RLU.0000000000000783.

136. Cimitan M, Evangelista L, Hodolic M, Mariani G, Baseric T, Bodanza V, et al. Gleason score at diagnosis predicts the rate of detection of 18F-choline PET/CT performed when biochemical evidence indicates recurrence of prostate cancer: experience with 1000 patients. *J Nucl Med*. 2015;56:209–15. doi:10.2967/jnumed.114.141887.

137. Evangelista L, Cimitan M, Zattoni F, Guttilla A, Zattoni F, Saladini G. Comparison between conventional imaging (abdominal-pelvic computed tomography and bone scan) and [(18)F]choline positron emission tomography/computed tomography imaging for the initial staging of patients with intermediate- to high-risk prostate cancer: a retrospective analysis. *Scand J Urol*. 2015;49:345–53. doi:10.3109/21681805.2015.1005665.

138. Mitchell CR, Lowe VJ, Rangel LJ, Hung JC, Kwon ED, Karnes RJ. Operational characteristics of (11)C-choline positron emission tomography/computerized tomography for prostate cancer with biochemical recurrence after initial treatment. *J Urol*. 2013;189: 1308–13. doi:10.1016/j.juro.2012.10.069.

139. Gillessen S, Omlin A, Attard G, de Bono JS, Efstathiou E, Fizazi K, et al. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. *Ann Oncol.* 2015;26: 1589–604. doi:10.1093/annonc/mdv257

Table 1

Performance of radiological techniques in assessing the presence of bone metastases in patients with prostate cancer

Technique	Reference	No. of patients	Sensitivity (%)	Specificity (%)	Positive predictive value (%)	Negative predictive value (%)	Accuracy (%)
Plain radiography (add-on to bone scan)	[77]	66	63	64	100	70	–
	[78]	14	58.6	–	–	–	–
	[79]	100	86	98	98	87	–
	Weighted mean		75.4	84.5	98.8	80.2	NE
Total		180					
CT (add-on to bone scan)	[80]	15	67	–	–	–	–
	[79]	66	100	88	100	100	–
MRI axial skeleton only	[80]	15	93	–	–	–	–
	Weighted mean		98.7	NE	NE	NE	NE
	Total	81					
Whole-body MRI with diffusion-weighted imaging	[80]	15	100	–	–	–	–
	[78]	14	96.4	–	–	–	–
	[81]	39	70	100	100	–	–
	[82]	49	100	87.2	–	–	–
	[83]	35	91	99	97	97	–
	[84]	49	100	98	83	100	98
	[79]	100	98	98	98	98	–
	[85]	23	80	98.2	–	–	–
	Weighted mean		93.2	96.6	94.9	98.3	NE
Total	324						

– not reported, *NE* not evaluated

Table 2

Performance of nuclear imaging techniques in patients with prostate cancer

Technique	Reference	No. of patients	Sensitivity (%)	Specificity (%)	Positive predictive value (%)	Negative predictive value (%)	Accuracy (%)
Bone scan	[103]	91	65.4	38.5	86.4	15.6	61.5
	[104]	50	50.8	82.2	86.4	42.9	60.6
	[97]	44	57	57	59	55	–
	[105]	18	87.5	80	–	–	–
	[106]	72	96.9	41.2	75.6	87.5	77.5
	[107]	97	96.4	75.3	98.1	61.4	–
	[108]	10	66.7	81.6	53.3	88.6	78
	[109]	37	89.3	–	–	–	–
	Weighted mean			78.5	59.3	83.2	52.5
Total	419						
SPET	[97]	44	78	67	72	74	–
	[107]	97	96.4	63.7	97.8	51.9	–
	Weighted mean		90.7	64.7	89.7	58.8	NE
	Total	141					
SPET/CT	[107]	97	96.4	94.2	98.5	87.1	
	[104]	50	93.1	54	81.8	77.9	81
	[97] <sup>a</sup>	44	100	62	74	100	–
	[97] <sup>b</sup>	44	100	100	100	100	–
	[110]	38	81	93	–	–	86
	[111]	42	91	83	–	–	88
	[105]	18	100	100	–	–	–
	[106]	72	100	70.6	86.5	100	65.4
	[108]	10	100	89.5	75	100	92
Weighted mean			95.5	77.4	85.1	94.9	78.5
Total	318						
<sup>18</sup> F-Fluoride PET/CT	[105]	18	55.6	80	–	–	–
	[106]	72	71.9	100	100	65.4	81.6
	Weighted mean		68.6	96	NE	NE	NE
	Total	90					
<sup>18</sup> F-FDG PET/CT	[110]	70	79	97	84	–	–
	[112]	26	96	100	–	–	–
	[104]	50	84.7	91.1	95	74.9	86.8
	[113]	38	74	99	–	–	88

Technique	Reference	No. of patients	Sensitivity (%)	Specificity (%)	Positive predictive value (%)	Negative predictive value (%)	Accuracy (%)
<sup>11</sup> C-Choline PET/CT	[111]	42	91	89	–	–	90
	[109]	37	82.7	–	–	–	–
	Weighted mean		83.5	94.9	88.6	NE	88.2
	Total	263					
	[114]	25	86	100	–	–	–
	[103]	91	96	92.3	98.7	80	95.6
	[115]	78	89	98	96	94	95
	[116]	95	81.3	98.7	–	–	95.8
	Weighted mean		88.4	96.6	97.5	86.5	95.5
	Total	289					

– not reported, *NE* not evaluated

<sup>a</sup>PET

<sup>b</sup>PET/CT



Table 3

Advantages and disadvantages of radiological and nuclear medicine techniques for detection and follow-up of bone metastases

Technique	Advantages	Disadvantages
Plain radiography	<ol style="list-style-type: none"> <li>1. High availability</li> <li>2. Low cost</li> <li>3. Easy for the patient</li> <li>4. Allows assessment of complications (e.g. fractures)</li> </ol>	<ol style="list-style-type: none"> <li>1. Low sensitivity and specificity</li> <li>2. Not all bones can be screened</li> <li>3. Does not allow assessment of therapeutic response</li> </ol>
CT	<ol style="list-style-type: none"> <li>1. High availability</li> <li>2. Allows assessment of fine bone details and characterization smaller lesions</li> <li>3. Allows detection of node and visceral metastases</li> </ol>	<ol style="list-style-type: none"> <li>1. High radiation dose</li> <li>2. Not used for systematic bone screening</li> <li>3. Not useful in assessment of therapy response</li> </ol>
MRI axial skeleton only	<ol style="list-style-type: none"> <li>1. Good availability</li> <li>2. Earlier detection of tumour foci</li> <li>3. Better diagnostic performance in detection and characterization of bone lesions</li> </ol>	<ol style="list-style-type: none"> <li>1. Bone metastases outside vertebral column or pelvic bones not detected</li> <li>2. Not used for detection of node or visceral metastases</li> <li>3. Not useful in assessment of therapy response</li> </ol>
MRI with whole-body and diffusion-weighted acquisitions	<ol style="list-style-type: none"> <li>1. Highest diagnostic performance in detection and characterization of bone lesions</li> <li>2. Allows detection and assessment of therapeutic response of node and visceral metastases</li> <li>3. Possible role of diffusion-weighted and anatomic imaging (3D T1-weighted) in assessment of therapeutic response</li> </ol>	<ol style="list-style-type: none"> <li>1. Advanced diagnostic techniques only available in specialist diagnostic imaging centres</li> <li>2. Longer duration of examination</li> <li>3. Higher cost</li> </ol>
Bone scan	<ol style="list-style-type: none"> <li>1. Low cost [104]</li> <li>2. High availability [104]</li> <li>3. Able to detect bone metastases several months before they are revealed by plain radiography</li> </ol>	<ol style="list-style-type: none"> <li>1. Low sensitivity for osteolytic lesions [97]</li> <li>2. No detection of bone marrow disease</li> <li>3. Poor sensitivity for osteolytic lesions without bone remodelling</li> </ol>

Technique	Advantages	Disadvantages
SPET	1. Improves the sensitivity of planar images	4. Low specificity (false-positive findings in case of degenerative changes, inflammatory processes, trauma, mechanical stress, and Paget's disease) [97] 5. Bone reactive changes necessary for optimal sensitivity [104] 6. Flare phenomenon due to some systemic treatments (also <sup>223</sup> Ra) [128] 1. Limited field of view [97]
SPET/CT	1. Improves the sensitivity of planar images 2. Improves the specificity of planar images [97]	2. Specificity not better than plain radiography 3. As bone scan (see above) [97] 1. Whole-body imaging not currently standard practice 2. Resource implications of increased cost, specialist equipment, and specialist manpower hours 3. Higher radiation dose than bone scan (3 – 5 mSv) 4. As bone scan (see above)
<sup>18</sup> F-Fluoride PET/CT	1. Elimination of fluoride from the blood is rapid. First pass elimination is 100 % vs. 64 % for diphosphonates 2. Superior image quality and therefore high diagnostic accuracy [105] 3. Rapid acquisition protocol (15 or 60 min after injection) 4. As <sup>99m</sup> Tc-diphosphonate, is able to identify high bone turnover and remodelling 5. Quantitative and automatic semiquantitative analyses of uptake in lesions [102]	1. Very sensitive to minimal degenerative changes 2. Higher cost and radiation dose compared with bone scan (from 3 to 5 – 7 mSv) [97] 3. Uncertain clinical impact when used to monitor treatment response 4. Flare phenomenon due to some systemic treatments (also <sup>223</sup> Ra) [127]
<sup>18</sup> F-FDG PET/CT	1. Can detect bone metastases at early stage of disease (bone marrow	1. Sclerotic metastases can be missed because of relatively small amount of

## Technique

## Advantages

## Disadvantages

involvement)

viable tumour tissue [126]

2. In osteolytic lesions and in presence of aggressive prostatic cancer, accumulation of tracer is higher for an increase in glycolytic rate [106]

2. FDG uptake limited in moderately or well-differentiated prostate cancer by low metabolism of the tissue [126]

3. Lack of FDG uptake in the osteoblastic lesion can be associated with the presence of quiescent cells

3. Higher cost and increased radiation dose compared with bone scan (from 3 to 5–7 mSv)

4. Superior image quality and therefore high diagnostic accuracy

5. Prognostic information [129]

6. Quantitative and automatic semiquantitative analyses of uptake in lesions [102]

1. More specific for prostate cancer

1. Flare phenomena reported during administration of abiraterone acetate and granulocyte-colony stimulating factor [121]

2. Able to identify three patterns of bone disease (bone marrow involvement, osteoblastic lesions, no active tumour) [110]

2.  $^{11}\text{C}$ -Choline not available in centres without on-site cyclotron

3. No uptake in chronic degenerative disease

3. High cost and increased radiation dose compared with bone scan (from 3 to 5–7 mSv)

4. Quantitative and automatic semiquantitative analyses of uptake in lesions [102]

$^{11}\text{C}/^{18}\text{F}$ -Choline  
PET/CT

Table 4

Performance of  $^{68}\text{Ga}$ -PSMA PET in the detection of bone metastases

Reference	No. patients	PSA level <sup>a</sup> (ng/mL)	Bone metastasis detection	
			Detection rate	Sensitivity (%)
[132]	5	–	–	Not available
[130]	319	4.59 (0.01 – 41,395)	359/901	Not available
[96]	37	4.0 (0.01 – 116)	23/78	Not available
[133]	38	1.72 ± 2.54	10/59	Not available
[131]	20	2.62 (0.51 – 73.6)	23/75	Not available
All	419	–	415/1,113 (37 %) <sup>b</sup>	–

<sup>a</sup>Expressed as median (range) or mean ± standard deviation, in accordance with available data<sup>b</sup>A lesion-based analysis was available in all studies

Table 5

Performance of radiolabelled choline PET in the detection of bone metastases

Reference	No. of patients	PSA level <sup>a</sup> (ng/mL)	Bone metastasis detection	
			Detection rate	Sensitivity (%)
[137]	48	12.71 <sup>b</sup> (2.80 – 581)	14	100
[134]	102	0.93 (0.67 – 1.10)	13	100
[138]	132	7.2 (2.2 – 1028)	26	Not available
[115]	78	2.4 (0.2 – 500)	24	89
[135]	140	4.9 (0.2 – 92)	70	Not available
[136]	1,000	3.30 (0.2 – 10,960)	335	80 (in 235 patients)
All	1,500	–	482 (32.1 %) <sup>c</sup>	–

<sup>a</sup>Expressed as median (range) or mean ± standard deviation, in accordance with available data<sup>b</sup>The study was performed at initial staging of disease<sup>c</sup>A patient-based analysis was available in all studies




Fig. 1 Whole-body MR images in a 69-year-old man with diffuse metastatic bone disease and signs of progression during antiandrogenic therapy. MR protocol corresponding whole-body 3D T1-weighted, STIR (short-tau inversion recovery) and diffusion-weighted images. Total scan time 54 min. a 3D coronal T1-weighted images with reconstructed sagittal and axial planes showing bone metastases as multiple hypointense foci involving vertebrae, ribs, hip, sternum and femurs. Early progression of disease is represented by the appearance of low signal intensity tissue adjacent to some of these foci (e.g. L2 and right iliac bone). b Corresponding STIR images confirm the predominantly osteosclerotic nature of the metastases which appear mostly hypointense; early progression of metastatic involvement is represented by the appearance of moderately high signal intensity bone changes. c DW images with 3D maximum intensity projection reconstruction identify early progression of disease as appearance of hyperintense bone foci representing tissue with restricted diffusion due to high cellularity. The remaining bone metastases are not clearly seen on the DW images, representing false-negative findings due to advanced sclerotic changes inside the lesions




Fig. 2

A 68-year-old man with prostate cancer treated by radical prostatectomy (pT3aN0Mx, Gleason score 10; positive margins and extracapsular invasion) and adjuvant radiotherapy in 2010. *May 2012* In 2012, for biochemical recurrence of disease (PSA 15.55 ng/mL), he was staged by  $^{18}\text{F}$ -choline PET/CT that showed metastatic bone recurrence of disease. He was started on bicalutamide and LHRH analogues. *October 2012* Due to a further increase in PSA (141 ng/mL after 4 months),  $^{18}\text{F}$ -choline PET/CT was repeated that showed progression of metastatic disease. Therefore, the attending oncologist suggested switching the treatment from androgen deprivation therapy to chemotherapy (docetaxel + prednisone). *February 2013* After 4 months, PSA had reduced to 33.6 ng/mL and  $^{18}\text{F}$ -choline PET/CT showed a good response to chemotherapy




Fig. 3

Diagnostic algorithm proposed for assessment of response to therapy in patients with metastatic prostate cancer (well-differentiated or low-risk prostate cancer is considered to be present in patients with a Gleason score of 6, moderately differentiated or intermediate-risk prostate cancer in patients with a Gleason score of 7, and poorly differentiated or high-risk prostate cancer in patients with a Gleason score of between 8 and 10) *wMRI* whole-body MRI